Filing Flows › Anika Therapeutics (ANIK) › Guidance history
Anika Therapeutics (ANIK) guidance history: what it guided and what it reported
Anika Therapeutics gave guidance in 3 earnings releases on file since Apr 29, 2026. Its releases raised guidance twice and lowered it once.
Adjusted EBITDA margin
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | 13.0%–17.0% (Jul 29, 2026) → raised 15.0%–17.0% (Nov 6, 2026) | — | to be reported | — |
The latest quarter
Anika Therapeutics, Q3 2026: revenue $30.6M (+10% year over year), operating margin -2.3%, net loss $311K, operating cash flow $8.4M. The chart follows the revenue to costs, profit and cash.
Questions
Does Anika Therapeutics beat its guidance?
Anika Therapeutics gave guidance in 3 earnings releases on file since Apr 29, 2026. Its releases raised guidance twice and lowered it once.
How often does Anika Therapeutics raise guidance?
Its earnings releases raised guidance twice and lowered it once since Apr 29, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.